Veradermics, Inc (MANE) stock
Close on Nov 11, 2026Market cap $6.54BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $6.54B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 8.21
- Dividend yield
- –
- Free cash flow yield
- -1.26%
Fundamentals
- Net income
- -$93.58M
- EPS, diluted
- -$40.02
- Free cash flow
- -$82.60M
- Book value per share
- $18.91
- Diluted shares
- 42M
Trading
- Next earnings
- Mar 29, 2027 (estimated, before the open)
- Previous close
- $148.44
- Open
- $148.74
- Day's range
- $146.73 – $156.63
- Volume
- 713,752
- Average volume (20 days)
- 644,754
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000 (since Feb 2026)
- RSI (14 days)
- 67.6
- Volatility (1 year)
- 91.6%
- Relative volume
- 0.96×
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MANE | S&P 500 | Difference | MANE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +19.6% | -2.4% | +22.0 pts | ||
| 3 months | +43.7% | -1.2% | +44.8 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Veradermics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Veradermics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical business focused on developing therapeutic treatments for common aesthetic and dermatological conditions. Its core initiative centers on treating pattern hair loss in men and women, an underserved condition characterized by high treatment failure and low satisfaction. The lead product candidate is VDPHL01, an oral extended-release minoxidil formulation engineered to stimulate hair growth while minimizing off-target cardiac stimulative risks. The company’s prospective customer base consists of male and female patients suffering from pattern hair loss.
Company profile, executives and historyVeradermics stock: common questions
What is Veradermics's stock price?
MANE closed at $156.56 on Nov 11, 2026, up 5.47% on the day.
What is Veradermics's market cap?
Veradermics was worth $6.54B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MANE's P/E ratio?
Veradermics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$40.02), so it has no meaningful P/E ratio.
Does Veradermics pay a dividend?
No. Veradermics has not paid a cash dividend over the last twelve months.
When does Veradermics report earnings next?
Veradermics is expected to report Q4 FY2026 results on Mar 29, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How many MANE shares are sold short?
3M shares were sold short at the latest FINRA report, 13.17% of the float, or 5.1 days of average trading volume.
Who are Veradermics's competitors?
Companies most similar to Veradermics by business, industry and size include VERU, PHVS, VRDN, VRCA, UPB.
See a number that looks wrong?